Cohen, Adam D. http://orcid.org/0000-0003-0939-3843
Parekh, Samir
Santomasso, Bianca D.
Gállego Pérez-Larraya, Jaime http://orcid.org/0000-0003-2969-0116
van de Donk, Niels W. C. J.
Arnulf, Bertrand
Mateos, Maria-Victoria http://orcid.org/0000-0003-2390-1218
Lendvai, Nikoletta
Jackson, Carolyn C.
De Braganca, Kevin C. http://orcid.org/0000-0001-7354-1244
Schecter, Jordan M.
Marquez, Loreta
Lee, Erin http://orcid.org/0000-0002-8728-7627
Cornax, Ingrid
Zudaire, Enrique
Li, Claire
Olyslager, Yunsi
Madduri, Deepu
Varsos, Helen
Pacaud, Lida
Akram, Muhammad
Geng, Dong
Jakubowiak, Andrzej http://orcid.org/0000-0002-2597-6822
Einsele, Hermann http://orcid.org/0000-0002-7680-0819
Jagannath, Sundar http://orcid.org/0000-0003-2934-6518
Funding for this research was provided by:
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.
Article History
Received: 15 September 2021
Revised: 1 February 2022
Accepted: 2 February 2022
First Online: 24 February 2022
Competing interests
: AC served in a consulting or advisory role for AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Genentech/Roche, Janssen, and Takeda, and received patents, royalties, and other intellectual property from Novartis. SJ is a consultant for Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. SP is supported by the National Cancer Institute (NCI) (R01 CA244899, CA252222) and receives research funding from Amgen, Bristol Myers Squibb, and Karyopharm. BS is an inventor on United States Provisional Patent Application No.: US20210181179A1 “Diagnosis and treatment of immunotherapy-induced neurotoxicity” filed by Memorial Sloan Kettering Cancer Center, served in a consulting or advisory role for Celgene, Janssen, Legend Biotech, Incyte, and In8bio, and received research funding from ADC Therapeutics. JGP-L served in a consulting or advisory role for Janssen, served in speakers bureau for Eisai, and received research funding from DNAtrix. NWCJvdD received grant support and advisory board fees from Bristol-Myers Squibb/Celgene, Janssen, Novartis, and Amgen, advisory board fees from Takeda, Servier, Bayer, Adaptive Biotechnologies, Roche, GlaxoSmithKline, and Sanofi, and grant support from Cellectis. BA served in a consulting or advisory role for Amgen, Celgene, and Janssen-Cilag, received travel expenses from Amgen, Celgene, Janssen-Cilag, Sanofi, and Takeda, received honoraria from Celgene, Janssen-Cilag, Sanofi, and Takeda, and received research funding from Janssen-Cilag. M-VM received consulting fees from Janssen-Cilag, GlaxoSmithKline, Celgene, Amgen, Regeneron, Pfizer, AbbVie, Takeda, Roche/Genentech, Sanofi, Oncopeptides, and Adaptive Biotechnologies. DM, KCDB, JMS, HV, LM, EL, IC, NL, YO, EZ, and CL are employees of Janssen. CCJ is an employee of Janssen and a consultant physician at the Memorial Sloan Kettering Cancer Center (New York, NY, USA). LP, MA, and DG are employees of Legend Biotech. AJ served in a consulting or advisory role for and received honoraria from AbbVie, Amgen, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Juno Therapeutics, Karyopharm Therapeutics, and Sanofi. HE served in a consulting or advisory role for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda, received travel expenses from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda, received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda, and received research funding from Amgen, Bristol-Myers Squibb, Celgene, and Janssen.